MediWound Ltd. (MDWD) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for MediWound Ltd. in 2026. The next earnings report is expected on November 17, 2026.
Next earnings date
17 Nov 2026
In 89 days
EPS estimate
-0.69
Revenue estimate
8.7M
Past earnings
Latest earnings analysis
MediWound Ltd. missed consensus on EPS but exceeded revenue estimates, with EPS of $-0.77 and revenue of $3.09 million, exceeding estimates by 19.4%. In the prior quarter EPS came in ahead of expectations while revenue fell short of estimates.
No dividend history available.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
MediWound Ltd. (MDWD) is scheduled to report earnings on November 17, 2026.
MediWound Ltd. (MDWD) last reported earnings on August 13, 2026.
MediWound Ltd. (MDWD) is listed on Nasdaq.
We use cookies to make our website work and improve your experience. With your consent, we also use cookies for analytics and advertising.